Verified Nov 2026
Batteries & E-Mobility
·

Alameda, California
·
Since 1994
Exelixis is a biopharmaceutical company founded in 1994 and headquartered in Alameda, California, with 1,000–5,000 employees and revenue in the $1–5 billion range. The company discovers and develops targeted small-molecule oncology therapies, with cabozantinib (marketed as CABOMETYX and COMETRIQ) as its flagship treatment for renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Exelixis serves the medical and pharmaceutical sectors through partnerships with major drug manufacturers.
Exelixis at a glance
Revenue
$1-5B
Est. band
Employees
1,000-5,000
Founded
1994
Headquarters
Alameda, California
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Exelixis is a biopharmaceutical company founded in 1994 and headquartered in Alameda, California, with 1,000–5,000 employees and revenue in the $1–5 billion range. The company discovers and develops targeted small-molecule oncology therapies, with cabozantinib (marketed as CABOMETYX and COMETRIQ) as its flagship treatment for renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Exelixis serves the medical and pharmaceutical sectors through partnerships with major drug manufacturers.
At a glance
Attribute | Detail |
|---|---|
Founded | 1994 |
Headquarters | Alameda, California |
Employees | 1,000-5,000 |
Revenue | $1-5B (estimated) |
Primary capability | Batteries & E-Mobility |
What Exelixis makes
The company manufactures multikinase inhibitor therapies targeting receptor tyrosine kinases to inhibit tumor growth in difficult-to-treat cancers.
Latest developments
2026-11-11 — Exelixis at Stifel 2026 Healthcare Conference: zanzalintinib push By Investing.com (investing.com)
2026-10-29 — Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update | Exelixis, Inc. (gcs-web.com)
2026-08-05 — Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update (businesswire.com)
2026-05-19 — Merck inks Keytruda supply pact to support Exelixis cancer trial (fiercebiotech.com)
2026-05-05 — Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update | Exelixis, Inc. (gcs-web.com)
2026-02-10 — Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update | Exelixis, Inc. (exelixis.com)
Facilities
Exelixis is headquartered in Alameda, California. Public sources also reference these locations:
Alameda, California — kinaxis.com
Company details
Exelixis collaborates with major pharmaceutical companies to expand the commercial reach and clinical application of its cancer medicines. Exelixis was founded in 1994, has an estimated 1,000-5,000 employees, and is headquartered in Alameda, California.
Frequently asked questions
What does Exelixis make?
Exelixis is a biopharmaceutical company founded in 1994 and headquartered in Alameda, California, with 1,000–5,000 employees and revenue in the $1–5 billion range. The company discovers and develops targeted small-molecule oncology therapies, with cabozantinib (marketed as CABOMETYX and COMETRIQ) as its flagship treatment for renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Exelixis serves the medical and pharmaceutical sectors through partnerships with major drug manufacturers.
Where is Exelixis headquartered?
Exelixis is headquartered in Alameda, California (1851 Harbor Bay Parkway, Alameda, California, 94502).
When was Exelixis founded?
Exelixis was founded in 1994.
How big is Exelixis?
Exelixis has an estimated 1,000-5,000 employees, with revenue in the $1-5B range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
